Four Next-Generation Alzheimer’s Drug Candidates Shaping the Future of Treatment

Alzheimer’s disease remains one of the most challenging areas in medicine, but a new wave of therapies is moving beyond traditional amyloid-only approaches. These next-generation candidates focus on tau pathology, RNA-based gene silencing, and improved brain delivery, signaling a broader and potentially more durable treatment landscape. Together, they highlight how the future of Alzheimer’s care may evolve toward earlier intervention, deeper disease modification, and combination strategies.

Biogen – BIIB080 (NASDAQ: BIIB)

Biogen is advancing BIIB080, an antisense oligonucleotide designed to reduce tau protein production at the genetic level. Unlike antibody therapies that target existing tau deposits, BIIB080 aims to limit tau accumulation upstream. The drug is currently in Phase 2 clinical development and has received FDA Fast Track designation. Early data showing reductions in tau biomarkers have helped position BIIB080 as one of the more closely watched tau-targeting programs in development.

Arrowhead Pharmaceuticals – ARO-MAPT (NASDAQ: ARWR)

Arrowhead Pharmaceuticals is applying its RNA interference (RNAi) platform to Alzheimer’s with ARO-MAPT, a therapy that silences the MAPT gene responsible for producing tau. By directly targeting gene expression, the approach may offer more sustained suppression than antibody-based treatments. Early-stage clinical data are expected in the coming years, and investors are watching closely to see whether Arrowhead’s RNAi expertise can translate into meaningful neurological outcomes.

Alnylam Pharmaceuticals – Mivelsiran (NASDAQ: ALNY)

Alnylam Pharmaceuticals is also leveraging RNAi technology with mivelsiran, an intrathecally delivered therapy designed to reduce pathological proteins linked to Alzheimer’s disease. Alnylam’s long track record in RNA-based medicines lends credibility to the program, even as it remains in earlier stages. The company’s focus on central nervous system delivery highlights growing confidence that RNA therapeutics can be adapted for complex neurological conditions.

Alector – AL137 (NASDAQ: ALEC)

Alector Therapeutics is taking a different approach with AL137, combining an anti-amyloid antibody with its proprietary blood–brain barrier transport technology. One of the biggest limitations of biologics in Alzheimer’s has been inefficient brain penetration, and Alector’s platform aims to address that challenge directly. While prior setbacks have tempered expectations, improved delivery could meaningfully enhance therapeutic effectiveness if clinical data support the approach.

Investor Perspective

For investors, these programs reflect a broader shift in Alzheimer’s drug development toward mechanism diversity and biological precision. Rather than relying on a single target, companies are increasingly exploring complementary pathways that could ultimately be combined into multi-drug regimens.

Key themes to watch include:

• Tau-focused strategies as potential complements to amyloid therapies
• RNA-based approaches that offer longer-lasting protein suppression
• Delivery innovations that improve drug access to the brain

Bottom Line

The next phase of Alzheimer’s innovation is moving upstream — toward gene regulation, tau biology, and smarter delivery systems. While clinical risk remains high, successful data from any of these programs could significantly reshape treatment standards and drive meaningful value creation. For investors, these next-generation candidates represent long-duration opportunities tied to one of the largest unmet medical needs in healthcare.